Last reviewed · How we verify
Teriparatide 40-mcg subcutaneous injection
At a glance
| Generic name | Teriparatide 40-mcg subcutaneous injection |
|---|---|
| Also known as | Forteo® |
| Sponsor | Massachusetts General Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption (PHASE4)
- A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen (PHASE1)
- Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia (PHASE2)
- Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: